DRRX : Summary for DURECT Corporation - Yahoo Finance

U.S. Markets closed

DURECT Corporation (DRRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.94-0.01 (-1.49%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.95
Bid0.00 x
Ask0.00 x
Day's Range0.94 - 0.99
52 Week Range0.91 - 2.00
Avg. Volume336,609
Market Cap133.41M
PE Ratio (TTM)-3.62
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube6 days ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis DURECT Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Impax Laboratories, Inc., Johnson & Johnson, Pfizer Inc., Pacira Pharmaceuticals, Inc., Heron Therapeutics Inc, Eli Lilly and Company and Corium International, ... Read more (Read more...)

  • PR Newswire7 days ago

    How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma

    Last Friday, shares in La Jolla, California headquartered Orexigen Therapeutics Inc. ended the session 3.76% lower at $4.10. The stock recorded a trading volume of 182,389 shares. The Company's shares have surged 141.18% in the previous three months and 135.63% on an YTD basis.

  • Associated Press12 days ago

    Durect reports 4Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...